With the sudden shift to minimize personal interaction and the refocusing of many hospitals on COVID-19, cross-functional launch teams must reconsider whether to launch, and if so, how to change their launch execution. In this Pharmaceutical Executive article, ZS experts Ben Hohn and Judith Kulich discuss how biopharma launches must adapt to new realities. Read the Pharmexec article.